159 related articles for article (PubMed ID: 19637127)
1. Cytomegalovirus gastritis after treatment with rituximab.
Hasegawa Y; Goto A; Nishimura S; Sukawa Y; Fujii K; Suzuki K; Yonezawa K; Abe T; Shinomura Y; Yoshida Y
Endoscopy; 2009; 41 Suppl 2():E199. PubMed ID: 19637127
[No Abstract] [Full Text] [Related]
2. Rituximab in diffuse large B-cell lymphoma.
Coiffier B
Clin Adv Hematol Oncol; 2004 Mar; 2(3):156-7. PubMed ID: 16166943
[No Abstract] [Full Text] [Related]
3. Diffuse large B-cell lymphoma on the back of a patient with AIDS: successful treatment by the CD20 monoclonal antibody rituximab.
Voigtländer C; Harrer T; Schneider L; Schulze-Koops H; Niedobitek G; Lüftl M
Int J Dermatol; 2005 Nov; 44(11):976-8. PubMed ID: 16336543
[No Abstract] [Full Text] [Related]
4. Fatal central nervous system lesions emerging during anti-CD20 monoclonal antibody therapy (Rituximab) for a post transplantation Epstein Barr virus-linked lymphoma.
Sirvent-Von Bueltzingsloewen A; Sirvent N; Morand P; Cassuto JP
Med Pediatr Oncol; 2003 Jun; 40(6):408-9. PubMed ID: 12692818
[No Abstract] [Full Text] [Related]
5. Enteroviral meningoencephalitis as complication of Rituximab therapy in a patient treated for diffuse large B-cell lymphoma.
Servais S; Caers J; Warling O; Frusch N; Baron F; De Prijck B; Beguin Y
Br J Haematol; 2010 Aug; 150(3):379-81. PubMed ID: 20408837
[No Abstract] [Full Text] [Related]
6. Enterovirus infection of neuronal cells post-Rituximab.
Kiani-Alikhan S; Skoulidis F; Barroso A; Nuovo G; Ushiro-Lumb I; Breuer J; Lister A; Mattes F
Br J Haematol; 2009 Aug; 146(3):333-5. PubMed ID: 19466969
[No Abstract] [Full Text] [Related]
7. Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy.
Horváth B; Demeter J; Eros N; Hársing J; Csomor J; Matolcsy A; Bottlik G; Gyori G; Marschalkó M; Kárpáti S
J Am Acad Dermatol; 2009 Nov; 61(5):885-8. PubMed ID: 19632742
[TBL] [Abstract][Full Text] [Related]
8. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice.
Mineo JF; Scheffer A; Karkoutly C; Nouvel L; Kerdraon O; Trauet J; Bordron A; Dessaint JP; Labalette M; Berthou C; Labalette P
Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):4738-45. PubMed ID: 18552383
[TBL] [Abstract][Full Text] [Related]
9. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K
Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus gastritis after rituximab treatment in a non-Hodgkn's lymphoma patient.
Unluturk U; Aksoy S; Yonem O; Bayraktar Y; Tekuzman G
World J Gastroenterol; 2006 Mar; 12(12):1978-9. PubMed ID: 16610013
[No Abstract] [Full Text] [Related]
11. Experimental treatment of human diffuse large B-cell lymphoma xenografts by doxycycline alone or in combination with the anti-CD20 chimeric monoclonal antibody rituximab.
Assayag F; Brousse N; Couturier J; Macintyre E; Mathiot C; Dewulf S; Froget B; Vincent-Salomon A; Decaudin D
Am J Hematol; 2009 Jun; 84(6):387-8. PubMed ID: 19373893
[No Abstract] [Full Text] [Related]
12. Rituximab for the treatment of CD20-positive peripheral T-cell lymphoma, unspecified.
Hirata Y; Yokote T; Kobayashi K; Nakayama S; Miyoshi T; Akioka T; Hara S; Tsuji M; Takubo T; Hanafusa T
Leuk Res; 2009 Jun; 33(6):e13-6. PubMed ID: 18995899
[No Abstract] [Full Text] [Related]
13. Waxing and waning intravascular large cell lymphoma with widespread organ infiltration.
Vos JM; Bordbar A; Vet RJ; Pals ST; Kater AP
Leuk Lymphoma; 2011 Apr; 52(4):705-8. PubMed ID: 21190427
[No Abstract] [Full Text] [Related]
14. Rituximab and statins.
Carver JR; Johnson T; Schuster SJ
J Clin Oncol; 2010 Oct; 28(30):e611; author reply e612. PubMed ID: 20805449
[No Abstract] [Full Text] [Related]
15. Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma.
Ozgönenel B; Moonka D; Savaşan S
Am J Hematol; 2006 Apr; 81(4):302. PubMed ID: 16550511
[No Abstract] [Full Text] [Related]
16. [Efficacy of rituximab therapy on diffuse large B-cell lymphoma with different Fcgamma RIIIA gene polymorphisms: a prospective study].
Zhang W; Wang X; Duan MH; Li J; Zhou DB
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(6):400-2. PubMed ID: 19567119
[TBL] [Abstract][Full Text] [Related]
17. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder.
Suzan F; Ammor M; Ribrag V
N Engl J Med; 2001 Sep; 345(13):1000. PubMed ID: 11575282
[No Abstract] [Full Text] [Related]
18. [Rituximab resistance in B-cell lymphoma and its elimination].
Hatake K; Terui Y
Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
[TBL] [Abstract][Full Text] [Related]
19. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody.
Matteucci P; Magni M; Di Nicola M; Carlo-Stella C; Uberti C; Gianni AM
Blood; 2002 Aug; 100(3):1104-5. PubMed ID: 12150156
[No Abstract] [Full Text] [Related]
20. Monoclonal antibodies and cytomegalovirus infections.
Damaj G; Charbonnier A; Bouabdallah R; Vey N; Coso D; Stoppa AM; Gastaut JA
Eur J Haematol; 2004 Jul; 73(1):73-4. PubMed ID: 15182343
[No Abstract] [Full Text] [Related]
[Next] [New Search]
